Protalix BioTherapeutics, Inc. (NYSE: PLX) 22% HIGHER; announced that it was approached by the FDA and asked to consider submitting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE